Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07144527
NA

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Sponsor: Scott Silveira

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Key Details

Gender

All

Age Range

60 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-02-21

Completion Date

2027-01-01

Last Updated

2026-02-20

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

NMN, betaine, low-dose hydrogen peroxide (EGA)

Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.

DIETARY_SUPPLEMENT

Nicotinamide Mononucleotide (NMN)

Conventional NMN supplement.

DIETARY_SUPPLEMENT

Placebo

Organoleptically matched inert control.

Locations (1)

Medical Office of Dr. Robert Huizenga MD

Beverly Hills, California, United States